6,900 Shares in Pfizer Inc. (PFE) Acquired by QUANTRES ASSET MANAGEMENT Ltd
QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,900 shares of the biopharmaceutical company’s stock, valued at approximately $243,000.
Several other hedge funds also recently modified their holdings of the company. Bloom Tree Partners LLC acquired a new stake in Pfizer during the first quarter valued at approximately $35,682,000. State of Alaska Department of Revenue increased its stake in Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock valued at $13,093,000 after buying an additional 37,647 shares during the period. BlackRock Group LTD increased its stake in Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock valued at $1,762,838,000 after buying an additional 3,154,116 shares during the period. Charter Trust Co. increased its stake in Pfizer by 4.3% in the second quarter. Charter Trust Co. now owns 377,918 shares of the biopharmaceutical company’s stock valued at $13,306,000 after buying an additional 15,510 shares during the period. Finally, Franklin Resources Inc. increased its stake in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock valued at $1,864,446,000 after buying an additional 9,005,107 shares during the period. Institutional investors and hedge funds own 69.66% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.94% on Thursday, hitting $32.76. 24,181,890 shares of the stock traded hands. The company’s 50 day moving average is $34.14 and its 200 day moving average is $34.26. The stock has a market cap of $198.71 billion, a price-to-earnings ratio of 29.04 and a beta of 0.86. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. Pfizer’s revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.56 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.66%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
Several analysts recently commented on the stock. Argus reiterated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research report on Sunday, August 28th. Jefferies Group downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $36.00 price target for the company. in a research report on Thursday. Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target for the company. in a research report on Tuesday, June 28th. Finally, Citigroup Inc. restated a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a research report on Wednesday, August 3rd. Eleven analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer currently has a consensus rating of “Buy” and an average price target of $38.66.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.